Tinktink
2021-11-18
Thanks
Life sciences software startup Benchling files for U.S. listing -sources<blockquote>生命科学软件初创公司正在为美国上市做准备——消息人士</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":878762424,"tweetId":"878762424","gmtCreate":1637235057274,"gmtModify":1637235057390,"author":{"id":3583431682924843,"idStr":"3583431682924843","authorId":3583431682924843,"authorIdStr":"3583431682924843","name":"Tinktink","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Thanks</p></body></html>","htmlText":"<html><head></head><body><p>Thanks</p></body></html>","text":"Thanks","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/878762424","repostId":1196614874,"repostType":4,"repost":{"id":"1196614874","kind":"news","pubTimestamp":1637234017,"share":"https://www.laohu8.com/m/news/1196614874?lang=zh_CN&edition=full","pubTime":"2021-11-18 19:13","market":"us","language":"en","title":"Life sciences software startup Benchling files for U.S. listing -sources<blockquote>生命科学软件初创公司正在为美国上市做准备——消息人士</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1196614874","media":"Reuters","summary":"Benchling, which develops software tools for scientists and pharmaceutical research organizations, h","content":"<p>Benchling, which develops software tools for scientists and pharmaceutical research organizations, has confidentially submitted paperwork with regulators for a stock market listing in New York, according to people familiar with the matter.</p><p><blockquote>据知情人士透露，为科学家和制药研究机构开发软件工具的Benchling已秘密向监管机构提交了在纽约股市上市的文件。</blockquote></p><p> The San Francisco, California-based company, which was valued at $4 billion in a funding round earlier this year, is aiming to go public in early 2022 at a much higher valuation, the sources said.</p><p><blockquote>消息人士称，这家总部位于加利福尼亚州旧金山的公司在今年早些时候的一轮融资中估值为40亿美元，计划在2022年初以更高的估值上市。</blockquote></p><p> Benchling is considering going public through a direct listing, although the company has not ruled out a traditional IPO (initial public offering), sources said. One of its major investors on the board, Benchmark Capital, has been a vocal advocate of direct listings.</p><p><blockquote>消息人士称，Benchling正在考虑通过直接上市的方式上市，尽管该公司没有排除传统的IPO（首次公开募股）。其董事会的主要投资者之一Benchmark Capital一直是直接上市的直言不讳的倡导者。</blockquote></p><p> The start-up hired investment banks and other financial advisors earlier this year to advise on its listing plans, the sources said.</p><p><blockquote>消息人士称，这家初创公司今年早些时候聘请了投资银行和其他财务顾问为其上市计划提供建议。</blockquote></p><p> The sources, who requested anonymity as these discussions are confidential, cautioned that Benchling's go-public plans were subject to market conditions and could change. Benchling declined to comment.</p><p><blockquote>由于这些讨论是保密的，要求匿名的消息人士警告说，Benchling的上市计划取决于市场条件，可能会发生变化。Benchling拒绝置评。</blockquote></p><p> Founded in 2012 by Massachusetts Institute of Technology classmates Sajith Wickramasekara and Ashu Singhal, Benchling has emerged as a prominent player in a niche and growing market for digitizing the R&D process.</p><p><blockquote>Benchling由麻省理工学院的同学Sajith Wickramasekara和Ashu Singhal于2012年创立，现已成为R&D流程数字化利基和不断增长的市场中的重要参与者。</blockquote></p><p> Its valuation has soared since the beginning of 2020, when it was valued at less than $1 billion, as the company benefited from booming R&D investments in pharma and biotech companies. Benchling has so far raised roughly $350 million from venture capital investors including Sequoia Capital and Menlo Ventures.</p><p><blockquote>自2020年初以来，其估值飙升，当时的估值不到10亿美元，因为该公司受益于制药和生物技术公司蓬勃发展的研发投资。迄今为止，Benchling已从红杉资本和Menlo Ventures等风险资本投资者那里筹集了约3.5亿美元。</blockquote></p><p> Benchling offers customers a variety of software applications and technology platforms, including cloud-based tools and laboratory automation software. Its end-to-end workflow management system allows researchers to collaborate and track projects.</p><p><blockquote>Benchling为客户提供各种软件应用和技术平台，包括基于云的工具和实验室自动化软件。其端到端工作流管理系统允许研究人员协作和跟踪项目。</blockquote></p><p> According to its website, over 200,000 scientists currently use Benchling's technology tools. It counts numerous big names from the pharma, life sciences and biotech sectors, including Gilead Sciences , Sanofi, Regeneron, Gingko Bioworks, Zymergen, Lyell Immunopharma Inc and BP's Biosciences Center among its customers.</p><p><blockquote>根据其网站，目前有超过200,000名科学家使用Benchling的技术工具。其客户包括制药、生命科学和生物技术领域的众多知名企业，包括吉利德科学、赛诺菲、再生元、Gingko Bioworks、Zymergen、Lyell Immunopharma Inc和BP生物科学中心。</blockquote></p><p> Earlier this year, Benchling hired former LinkedIn executive Richard Wong as its chief financial officer as part of its plans to go public.</p><p><blockquote>今年早些时候，Benchling聘请LinkedIn前高管Richard Wong担任首席财务官，作为其上市计划的一部分。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Life sciences software startup Benchling files for U.S. listing -sources<blockquote>生命科学软件初创公司正在为美国上市做准备——消息人士</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLife sciences software startup Benchling files for U.S. listing -sources<blockquote>生命科学软件初创公司正在为美国上市做准备——消息人士</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-18 19:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Benchling, which develops software tools for scientists and pharmaceutical research organizations, has confidentially submitted paperwork with regulators for a stock market listing in New York, according to people familiar with the matter.</p><p><blockquote>据知情人士透露，为科学家和制药研究机构开发软件工具的Benchling已秘密向监管机构提交了在纽约股市上市的文件。</blockquote></p><p> The San Francisco, California-based company, which was valued at $4 billion in a funding round earlier this year, is aiming to go public in early 2022 at a much higher valuation, the sources said.</p><p><blockquote>消息人士称，这家总部位于加利福尼亚州旧金山的公司在今年早些时候的一轮融资中估值为40亿美元，计划在2022年初以更高的估值上市。</blockquote></p><p> Benchling is considering going public through a direct listing, although the company has not ruled out a traditional IPO (initial public offering), sources said. One of its major investors on the board, Benchmark Capital, has been a vocal advocate of direct listings.</p><p><blockquote>消息人士称，Benchling正在考虑通过直接上市的方式上市，尽管该公司没有排除传统的IPO（首次公开募股）。其董事会的主要投资者之一Benchmark Capital一直是直接上市的直言不讳的倡导者。</blockquote></p><p> The start-up hired investment banks and other financial advisors earlier this year to advise on its listing plans, the sources said.</p><p><blockquote>消息人士称，这家初创公司今年早些时候聘请了投资银行和其他财务顾问为其上市计划提供建议。</blockquote></p><p> The sources, who requested anonymity as these discussions are confidential, cautioned that Benchling's go-public plans were subject to market conditions and could change. Benchling declined to comment.</p><p><blockquote>由于这些讨论是保密的，要求匿名的消息人士警告说，Benchling的上市计划取决于市场条件，可能会发生变化。Benchling拒绝置评。</blockquote></p><p> Founded in 2012 by Massachusetts Institute of Technology classmates Sajith Wickramasekara and Ashu Singhal, Benchling has emerged as a prominent player in a niche and growing market for digitizing the R&D process.</p><p><blockquote>Benchling由麻省理工学院的同学Sajith Wickramasekara和Ashu Singhal于2012年创立，现已成为R&D流程数字化利基和不断增长的市场中的重要参与者。</blockquote></p><p> Its valuation has soared since the beginning of 2020, when it was valued at less than $1 billion, as the company benefited from booming R&D investments in pharma and biotech companies. Benchling has so far raised roughly $350 million from venture capital investors including Sequoia Capital and Menlo Ventures.</p><p><blockquote>自2020年初以来，其估值飙升，当时的估值不到10亿美元，因为该公司受益于制药和生物技术公司蓬勃发展的研发投资。迄今为止，Benchling已从红杉资本和Menlo Ventures等风险资本投资者那里筹集了约3.5亿美元。</blockquote></p><p> Benchling offers customers a variety of software applications and technology platforms, including cloud-based tools and laboratory automation software. Its end-to-end workflow management system allows researchers to collaborate and track projects.</p><p><blockquote>Benchling为客户提供各种软件应用和技术平台，包括基于云的工具和实验室自动化软件。其端到端工作流管理系统允许研究人员协作和跟踪项目。</blockquote></p><p> According to its website, over 200,000 scientists currently use Benchling's technology tools. It counts numerous big names from the pharma, life sciences and biotech sectors, including Gilead Sciences , Sanofi, Regeneron, Gingko Bioworks, Zymergen, Lyell Immunopharma Inc and BP's Biosciences Center among its customers.</p><p><blockquote>根据其网站，目前有超过200,000名科学家使用Benchling的技术工具。其客户包括制药、生命科学和生物技术领域的众多知名企业，包括吉利德科学、赛诺菲、再生元、Gingko Bioworks、Zymergen、Lyell Immunopharma Inc和BP生物科学中心。</blockquote></p><p> Earlier this year, Benchling hired former LinkedIn executive Richard Wong as its chief financial officer as part of its plans to go public.</p><p><blockquote>今年早些时候，Benchling聘请LinkedIn前高管Richard Wong担任首席财务官，作为其上市计划的一部分。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/life-sciences-software-startup-benchling-110000545.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/life-sciences-software-startup-benchling-110000545.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196614874","content_text":"Benchling, which develops software tools for scientists and pharmaceutical research organizations, has confidentially submitted paperwork with regulators for a stock market listing in New York, according to people familiar with the matter.\nThe San Francisco, California-based company, which was valued at $4 billion in a funding round earlier this year, is aiming to go public in early 2022 at a much higher valuation, the sources said.\nBenchling is considering going public through a direct listing, although the company has not ruled out a traditional IPO (initial public offering), sources said. One of its major investors on the board, Benchmark Capital, has been a vocal advocate of direct listings.\nThe start-up hired investment banks and other financial advisors earlier this year to advise on its listing plans, the sources said.\nThe sources, who requested anonymity as these discussions are confidential, cautioned that Benchling's go-public plans were subject to market conditions and could change. Benchling declined to comment.\nFounded in 2012 by Massachusetts Institute of Technology classmates Sajith Wickramasekara and Ashu Singhal, Benchling has emerged as a prominent player in a niche and growing market for digitizing the R&D process.\nIts valuation has soared since the beginning of 2020, when it was valued at less than $1 billion, as the company benefited from booming R&D investments in pharma and biotech companies. Benchling has so far raised roughly $350 million from venture capital investors including Sequoia Capital and Menlo Ventures.\nBenchling offers customers a variety of software applications and technology platforms, including cloud-based tools and laboratory automation software. Its end-to-end workflow management system allows researchers to collaborate and track projects.\nAccording to its website, over 200,000 scientists currently use Benchling's technology tools. It counts numerous big names from the pharma, life sciences and biotech sectors, including Gilead Sciences , Sanofi, Regeneron, Gingko Bioworks, Zymergen, Lyell Immunopharma Inc and BP's Biosciences Center among its customers.\nEarlier this year, Benchling hired former LinkedIn executive Richard Wong as its chief financial officer as part of its plans to go public.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1976,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/878762424"}
精彩评论